Related Story
For part 2 of this article, read "Purification of Antibodies Using Novel Convecdiff Membranes Part 2: Robust Performance at Comparable Product Quality" in the Feb. 1, 2023 issue of BioPharm International.
Purification of Antibodies Using Novel Convecdiff Membranes Part 1: Providing High Binding Capacity at Short Residence Time and Low Pressure Drops
Publication
Article
BioPharm InternationalBioPharm International, January 2023
Volume 36
Issue 01
Pages: 22–27
The testing of new convecdiff membranes shows this material to be well suited for lab- and commercial-scale bind-and-elute applications.
Siarhei/Stock.adobe.com
Convecdiff membranes, a new type of chromatographic material that combines high protein-binding capacity with high productivity while providing scalability, are introduced. The convecdiff membrane prototypes presented in this study reach a dynamic binding capacity of approximately 40 g/L at residence times in the seconds range while pressure drop is below 2.5 bar at a bed height of several millimeters. The robustness of the new material is proven up to 200 cycles. The material performance regarding yield, impurity reduction, and other results observed during cycling is comparable to the performance of established materials, and no performance decline occurred during cycling. With all these characteristics, the material is well suited for protein bind-and-elute applications ranging from laboratory to production scale.
Peer-reviewed research
Submitted: March 2, 2022
Accepted: July 21, 2022
About the authors
Katrin Töppner*, Katrin.Toeppner@Sartorius.com, is Product Development (PD) scientist; Patrick Adametz*, Patrick.Adametz@Sartorius.com, is process engineer; Ricarda A. Busse is product manager for Membrane Chromatography Consumables; and Volkmar Thom is head of PD Purification Materials; all at Sartorius Stedim Biotech. Chaz Goodwine is lead downstream scientist at AGC Biologics.
*To whom all correspondence should be addressed.
Article details
BioPharm International
Vol. 36, No. 1
January 2023
Pages: 22–27
Citation
When referring to this article, please cite it as Töppner, K; Adametz, P.; Goodwine, C.; Busse, R.A.; Thom, V. Complex Analytical Workflows Increasingly Require Robust Bioassays. BioPharm International 2023, 36 (1), 22–27.
Articles in this issue
Accepting Alternative Approaches to Freeze Drying
Six Approaches Making the Most Significant Impact in the Future
Crossing the Same River Multiple Times
Purification of Antibodies Using Novel Convecdiff Membranes Part 1: Providing High Binding Capacity at Short Residence Time and Low Pressure Drops
Choosing the Right Resins for Viral Vector Affinity Chromatography
Safeguarding Biologics— Blending Engineering Ingenuity and Managerial Excellence
Complex Analytical Workflows Increasingly Require Robust Bioassays
A Rocky Road Ahead for FDA and Industry
Creating a Contamination Control Strategy
Pedestrians as Priority
Paradigm Shift
Recent Videos
